In Silico Genesis invited by UKTI Japan to present at British Embassy Tokyo on UKTI CNS Trade Mission.

In Silico Genesis received an invitation by a representative of UKTI Japan, to present the last slot of UKTI CNS Trade Mission’s seminars held in British Embassy Tokyo on Friday, the 7th of November, 2014.

This generosity has been made possible by a fellow British delegate who presented at British Embassy Seoul, alongside with the presentation by In Silico Genesis on Tuesday, the 4th of November, 2014.

Kimberley of In Silico Genesis is deeply thankful to UKTI Japan and the central CNS Trade Mission team in London altogether, making this amazing opportunity possible.

In Silico Genesis is on UK Trade & Investment CNS mission to British Embassy Seoul of South Korea in November, 2014.

ISG is hitting Seoul in the first week of November 2014, to represent the CNS work done by this British Company in the foreign soil, for the first time in the company’s history, since early 2011. Come and see us, if you want to see what we are made of in real. I am proud of UK Trade and Investment for making this very unlikely mission possible.

 

In Silico Genesis receives another United Kingdom Excellence Award by US Institute for Advancement of Trade and Commerce.

In Silico Genesis receives 2014 United Kingdom Excellence Award

August 15th 2014 – In Silico Genesis has been selected for the 2014 United Kingdom Excellence Award amongst all its peers and competitors by the US Institute for Advancement of Trade & Commerce (USIATC).

Each year the USIATC conducts business surveys and industry research to identify companies that have achieved demonstrable success in their local business environment and industry category. They are recognized as having enhanced the commitment and contribution of small businesses through service to their customers and community. Small businesses of this caliber enhance the consumer driven stature that United Kingdom is renowned for.

In Silico Genesis has consistently demonstrated a high regard for upholding business ethics and company values. This recognition by USIATC marks a significant achievement as an emerging leader within various competitors and is setting benchmarks that the industry should follow.

As part of the industry research and business surveys, various sources of information were gathered and analyzed to choose the selected companies in each category. This research is part of an exhaustive process that encapsulates a year long immersion in the British business climate.

About USIATC

The USIATC is a leading authority on researching, evaluating and recognizing companies across a wide spectrum of industries that meet its stringent standards of excellence. It has spearheaded the idea of independent enterprise and entrepreneurial growth allowing businesses of all sizes to be recognized locally and encouraged globally.

Particular emphasis is given to meeting and exceeding industry benchmarks for customer service, product quality and ethical practices. Industry leading standards and practices have been developed and implementation of the same has been pioneered by the dedicated efforts of the business community and commerce leadership.

More information on USIATC can be found at http://www.USIATC.org

ISG receives United Kingdom Excellence Award by US Trade and Commerce Institute.

FOR IMMEDIATE RELEASE:

In Silico Genesis receives 2013 United Kingdom Excellence Award

May 24th 2014 – In Silico Genesis has been selected for the 2013 United Kingdom Excellence Award amongst all its peers and competitors by the US Trade & Commerce Institute (USTCI).

Each year the USTCI conducts business surveys and industry research to identify certain international companies that have achieved demonstrable success in their local business environment and industry category. They are recognized as having enhanced the commitment and contribution of small businesses through service to their customers and community. Companies of this caliber enhance the consumer driven stature that the United Kingdom economy is renowned for.

In Silico Genesis has consistently demonstrated a high regard for upholding business ethics and company values. This recognition by USTCI marks a significant achievement as an emerging leader within various competitors and is setting benchmarks that the industry should follow.

As part of the industry research and business surveys, various sources of information were gathered and analyzed to choose the selected companies in each category. This research is part of an exhaustive process that encapsulates a year long immersion in the business climate of the United Kingdom economy.

About USTCI

The USTCI is a leading authority on researching, evaluating and recognizing companies across a wide spectrum of industries that meet its stringent standards of excellence. It has spearheaded the idea of independent enterprise and entrepreneurial growth allowing businesses of all sizes to be recognized locally and encouraged globally.

Particular emphasis is given to meeting and exceeding industry benchmarks for customer service, product quality and ethical practices. Industry leading standards and practices have been developed and implementation of the same has been pioneered by the dedicated efforts of the business community and commerce leadership.

More information on USTCI can be found at http://www.USTCI.org

Operations in the Far East

In Silico Genesis has established a point of contact in the Far East as of April, 2014. Tel/Fax: +82 (0)55 364 1620

Picture inset: Kimberley’s father, Advisor for Operations in the Far East.

Shown below is an executive summary of In Silico Genesis.

In Silico Genesis was founded in early 2011, primarily based on the work carried out in the Laboratory of Molecular Biophysics and the Structural Bioinformatics and Computational Biochemistry Unit, the Department of Biochemistry of the University of Oxford. The Medical Research Council provided the funding for the research and training undertaken, via MRC special training fellowship in Bioinformatics/Neuroinformatics/Health-Informatics, under a project title “Ion channels and their regulatory interactions – a bioinformatics approach”.

In Silico Genesis does a target-driven translation for developing genomic medicine and companion diagnostics. The company has three portfolios in the production line at present, which has been made possible via in kind support provided by the Oxford Supercomputing Centre in the Oxford e Research Centre of the University of Oxford. In Silico Genesis has a target identified for three existing antimalarials in the market (malaria companion diagnostics), an antiviral combination therapy consisting of oligonucleotides and a repurposed drug for influenza A virus (biohazard level 2) and Crimean Congo Haemorrhagic Fever virus (biohazard level 4), and a three-component Alzheimer’s therapy aided by a viral vector for delivery in the brain. The company operates in partnership with the Public Health England for our virus programme and is collaborating with Pharmacology, the University of Oxford for one of our Alzheimer’s projects.

Specialties: Medical genomics, bioinformatics, medical statistics and biochemistry

Kimberley of In Silico Genesis Limited (ISG) is thankful to Dr. Mark Treherne, Chief Executive of UK Trade and Investment (UKTI), Life Science Investment Organisation (LSIO) in Cambridge of England, for his unshakable confidence and trust since the year of foundation of In Silico Genesis.

ISG – UN Global Marketplace Vendor ID : 361253

In Silico Genesis Limited – UN Global Marketplace Vendor ID : 361253

The status of In Silico Genesis Limited with the following UN organizations under UNGM: Successfully registered as shown below, as of 28th of February 2014.

Asian Development Bank (ADB)
African Development Bank Group (AFDB)
Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO)
Food and Agriculture Organization of the United Nations (FAO)

International Atomic Energy Agency (IAEA)
International Fund for Agricultural Development (IFAD)
International Labour Organization (ILO)
International Trade Centre (ITC)
International Telecommunication Union (ITU)
Organization for the Prohibition of Chemical Weapons (OPCW)
Joint United Nations Programme on HIV/AIDS (UNAIDS)
United Nations Development Programme (UNDP)
United Nations Educational, Scientific and Cultural Organization (UNESCO)
United Nations Population Fund (UNFPA)
Office of the United Nations High Commissioner for Refugees (UNHCR)
United Nations Children’s Fund (UNICEF)
United Nations Office for Project Services (UNOPS)
United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA)
World Health Organization (WHO)
World Intellectual Property Organization (WIPO)
World Meteorological Organization (WMO)

ISG signs CDA with Oxford University Innovation (previously known as ISIS Innovation), the University of Oxford and Baroness Susan Greenfield.

In Silico Genesis signed up a Confidential Disclosure Agreement with ISIS Innovation, the commercial arm of the University of Oxford, and the University of Oxford and plus Baroness Professor Susan Greenfield of Pharmacology of the University of Oxford in June 2013. This 4 way CDA was put in place, following an initial collaborative work with Prof. Greenfield’s lab on a repurposed drug for Alzheimer’s Disease.

ISG signs CDA with Public Health England, Department of Health under HM Government.

In Silico Genesis signed up a Confidential Disclosure Agreement with Public Health England (PHE), previously Health Protection Agency, in June 2013. This CDA was reaffirming an initial CDA placed in October, 2011 between Health Protection Agency (HPA) and In Silico Genesis (ISG) about the antiviral work in collaboration. 

Public Health England (PHE) https://www.gov.uk/government/organisations/public-health-england

ISG presents in One Nucleus CNS Leadership Seminar series in London.

In Silico Genesis presented our Alzheimer’s strategy to the One Nucleus CNS Leadership Seminar Series held in London, on the 11th of Feb. 2013.

This seminar will look at:

• The Prime Minister’s Dementia Challenge
• Pharmacotherapy for Alzheimer’s disease – progress and prospects
• The emerging scientific advances that may enable greater success in the future

Agenda:

10.30 – Registration

11.00 – Welcome from the Chair
Janet Knowles, Partner, Eversheds

11.10 – The Prime Minister’s Dementia Challenge
Mark Treherne, CEO, Life Sciences Investment Organisation, UKTI

11.30 – What are the prospects of slowing the progression of Alzheimer’s disease?
Prof Alan Palmer, Director MS Therapeutics

12.00 – What insights do biomarkers provide into the recent Phase III failures?
Andrea Les, Senior Imaging Scientist, IXICO

12.20 – Q&A with the speakers

12.45 – Networking Lunch

13.45 – Introduction from the Chair
Philip Oliver

13.45 Is there a future for the amyloid theory in treating Alzheimer’s disease?
Eric Karran, Alzheimer’s Research UK

14.05 Targeting Tau hyperphosporylation in AD
Ian Pike, COO, Proteome Sciences

14.25 – Genetic basis of Alzheimer disease susceptibility
Prof. Julie Williams, Cardiff University School of Medicine

14.45 – FGL Peptides as neuroprotectives in AD
Steve Rees, COO, ENKAM Pharmaceuticals A/S

15.05 – Translational genomic medicine and companion diagnostic development
Kimberley Treherne (then, Williams), In Silico Genesis

15.25 – Closing Remarks from one Nucleus
Tony Jones, Director of Business Development, One Nucleus

15.30 – Networking drinks

16.30 – Close

Shown above can be found at http://onenucleus.com/onenucleus-events?id=692.

An Ion Channel Database – Annotation via Homology Modelling

An Ion Channel Database – Annotation via Homology Modelling

This is an electronic copy of poster presentation at Cold Spring Harbor Laboratory conference jointed held with the Wellcome Trust Genome Campus in Hinxton, England. It is welcome for anyone to view the work via clicking the link or to download a copy of the digital version of this presentation.

It briefly addresses the construction of genomic database (of ion channel proteins, in this case), which focused particularly on potassium channels and nicotinic acetylcholine receptors. Target sequences of interest can be studied further to understand how they may function biologically, by means of pairwise alignment (2D) and computational models (3D) provided any significant homology detected from the previous alignment.